-
Net Sales are expected to increase by 5.2 percent Y-o-Y (up 7.7 percent Q-o-Q) to Rs 13,628.1 crore, according to ICICI Securities.
-
Sun Pharma Q3: Management indicated that the launch of Leqselvi could be delayed until December 2026 if the company does not secure a favourable judgment in the ongoing patent infringement case.
-
Sun Pharma's Q3 earnings may see a slight setback in margins, pressured by increased R&D expenses and a lower contribution from cancer drug Revlimid.
-
Sun Pharma's performance in the US market will be driven by ramp-up of Revlimid, resumption of supplies from Mohali unit and growth in its specialty portfolio. Back home, its robust foothold in the chronic segment promises to fuel double-digit growth.
-
Analysts expect a ramp-up in select specialty products to offset some impact of restrictions at Halol and Mohali plants for Sun Pharma.
-
Net Sales are expected to increase by 9.5 percent Y-o-Y (up 7.8 percent Q-o-Q) to Rs 11,784.7 crore, according to Nirmal Bang.
-
Net Sales are expected to increase by 14 percent Y-o-Y (up 2.7 percent Q-o-Q) to Rs 1,12,458 crore, according to Nirmal Bang.
-
Sun Pharmaceutical’s consolidated revenues, however, are expected to rise 13.2 percent on a year-on-year basis aided by growth in US specialty products and domestic formulations portfolio
-
The YoY growth is likely to be driven by growth in US business, strong performance from specialty product portfolio, and modest growth in domestic formulations. Margins however, are likely to take a dent due to inflationary pressures
-
Net Sales are expected to increase by 6.8 percent Y-o-Y (up 9.9 percent Q-o-Q) to Rs 10,382.7 crore, according to ICICI Direct.
-
Net Sales are expected to increase by 4.9 percent Y-o-Y (down 8 percent Q-o-Q) to Rs 10,198 crore, according to Prabhudas Lilladher.
-
Net sales for the quarter likely to rise 11.5 percent year-on-year growth to Rs 9853 crore for the December quarter
-
Net Sales are expected to increase by 12.7 percent Y-o-Y (up 0.3 percent Q-o-Q) to Rs 8,547.7 crore, according to KRChoksey.
-
Net Sales are expected to increase by 19.5 percent Y-o-Y (up 6.3 percent Q-o-Q) to Rs 9062.7 crore, according to ICICI Direct.
-
The pharma major is likely to report a more than 100 percent year-on-year growth in profit, backed by healthy operating performance, and low base in the year-ago quarter.
-
Net Sales are expected to increase by 6.2 percent Y-o-Y (down 1.6 percent Q-o-Q) to Rs. 8,692.6 crore, according to Sharekhan.
-
Brokerage firm Motilal Oswal Financial Services expects a 65.7 percent YoY rise in adjusted net profit and a 7.3 percent YoY rise in revenue for the quarter.
-
Net Sales are expected to increase by 7.7 percent Y-o-Y (up 2.7 percent Q-o-Q) to Rs. 8,782.1 crore, according to Yash Securities.
-
Net Sales are expected to increase by 5.9 percent Y-o-Y (up 1 percent Q-o-Q) to Rs. 8,636 crore, according to ICICI Direct.
-
Sun Pharma's key facility Halol continues to be under FDA issue which has slowed down new approvals.
-
On the operating front, earnings before interest, tax, depreciation and amortisation (EBITDA) is expected to rise around 60 percent and margin may expand by more than 650 basis points YoY.
-
Net Sales are expected to increase by 15.2 percent Y-o-Y (down 4.6 percent Q-o-Q) to Rs. 7,988.9 crore, according to Emkay.
-
Net Sales are expected to increase by 8 percent Y-o-Y (up 9.4 percent Q-o-Q) to Rs. 7,709.3 crore, according to Prabhudas Lilladher.
-
Numbers, reported on May 28 after market hours, were below analyst estimates but adjusted earnings were in line with expectations
-
Net Sales are expected to increase by 8.1 percent Y-o-Y (down 5.3 percent Q-o-Q) to Rs. 7,252.9 crore, according to Prabhudas Lilladher.
